EMA Application withdrawn: Rotigotine Mylan (rotigotine) — Mylan S.A.S

View source ↗

Summary

The EMA has withdrawn the marketing authorization application for Rotigotine Mylan (rotigotine) submitted by Mylan S.A.S, for restless legs syndrome and Parkins…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease
• Restless Legs Syndrome

Drugs mentioned

• Rotigotine Mylan (rotigotine)

Snippet

Status: Application withdrawn. Therapeutic area: Restless Legs Syndrome;Parkinson Disease. MAH: Mylan S.A.S. Decision date: 26/01/2018